MSS/ MMRp
Quiénes somos
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Estudio de fase 2 de CA102N combinado con TAS-102 comparado con bevacizumab combinado con TAS-102 en sujetos con cáncer colorrectal metastásico recidivante y/o refractario.
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Estudio de CNA3103 (células CAR-T autólogas dirigidas a LGR5) administrado a sujetos con cáncer colorrectal metastásico.
RC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
